Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas.

endonasal endoscopic follow-up long-term outcomes macroadenoma non–hormone producing pituitary adenoma pituitary surgery transsphenoidal

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
31 Jan 2020
Historique:
received: 18 09 2019
accepted: 20 11 2019
medline: 1 2 2020
pubmed: 1 2 2020
entrez: 1 2 2020
Statut: epublish

Résumé

Nonfunctioning pituitary adenomas are benign, slow-growing tumors. After gross-total resection (GTR) or subtotal resection (STR), tumors can recur or progress and may ultimately require additional intervention. A greater understanding of long-term recurrence and progression rates following complete or partial resection and the need for further intervention will help clinicians provide meaningful counsel for their patients and assist data-driven decision-making. The authors retrospectively analyzed their institutional database for patients undergoing endoscopic endonasal surgery (EES) for nonfunctioning pituitary macroadenomas (2003-2014). Only patients with follow-up of at least 5 years after surgery were included. Tumor volumes were measured on pre- and postoperative MRI. Tumor recurrence was defined as the presence of a 0.1-cm3 tumor volume after GTR, and tumor progression was defined as a 25.0% increase in residual tumor after STR. A total of 190 patients were included, with a mean age of 63.8 ± 13.2 years; 79 (41.6%) were female. The mean follow-up was 75.0 ± 18.0 months. GTR was achieved in 127 (66.8%) patients. In multivariate analysis, age (p = 0.04), preoperative tumor volume (p = 0.03), Knosp score (p < 0.001), and Ki-67 (p = 0.03) were significant predictors of STR. In patients with GTR, the probability of recurrence at 5 and 10 years was 3.9% and 4.7%, and the probability of requiring treatment for recurrence was 0.79% and 1.6%, respectively. In 63 patients who underwent STR, 6 (9.5%) received early postoperative radiation and did not experience progression, while the remaining 57 (90.5%) were observed. Of these, the probability of disease progression at 5 and 10 years was 21% and 24.5%, respectively, and the probability of requiring additional treatment for progression was 17.5% and 21%. Predictors of recurrence or progression in the entire group were Knosp score (p < 0.001) and elevated Ki-67 (p = 0.03). Significant predictors of progression after STR in those who did not receive early radiotherapy were cavernous sinus location (p < 0.05) and tumor size > 1.0 cm3 (p = 0.005). Following GTR for nonfunctioning pituitary adenomas, the 10-year chance of recurrence is low and the need for treatment even lower. After STR, although upfront radiation therapy may prevent progression, even without radiotherapy, the need for intervention at 10 years is only approximately 20% and a period of observation may be warranted to prevent unnecessary prophylactic radiation therapy. Tumor volume > 1 cm3, Knosp score ≥ 3, and Ki-67 ≥ 3% may be useful metrics to prompt closer follow-up or justify early prophylactic radiation therapy.

Identifiants

pubmed: 32005016
doi: 10.3171/2019.11.JNS192457
pii: 2019.11.JNS192457
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

535-546

Auteurs

Mina M Gerges (MM)

Departments of1Neurosurgery.
2Department of Neurosurgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Kavelin Rumalla (K)

6Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.

Saniya S Godil (SS)

Departments of1Neurosurgery.
3Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee; and.

Iyan Younus (I)

5Weill Cornell Medical College, New York, New York.

Walid Elshamy (W)

2Department of Neurosurgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Georgiana A Dobri (GA)

Departments of1Neurosurgery.
7Endocrinology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York.

Ashutosh Kacker (A)

4Otolaryngology, and.

Abtin Tabaee (A)

4Otolaryngology, and.

Viay K Anand (VK)

4Otolaryngology, and.

Theodore H Schwartz (TH)

Departments of1Neurosurgery.
4Otolaryngology, and.

Classifications MeSH